Fatty Liver Disease and Multi-System Complications Hepatobiliary Cancers: Pathobiology and Translational Advances
The program will explore current challenges in the field, including (1) shifting etiological trends, focusing on mechanisms linked to cell injury, inflammation, and fibrogenesis; (2) roles of the microbiome and tumor microenvironment in affecting disease progression, therapeutic resistance, and immunosurveillance; (3) challenges of inter-and intra-tumoral heterogeneity; (4) identification of novel and more effective biomarker signatures for monitoring prognosis and treatments; (5) advances in “omics” for personalizing therapies; and (6) current and emerging trends in molecular and immune targeting. Moreover, this unique meeting is paired with a joint meeting on fatty liver disease, which is a perfect fit in lieu of the fact that non-alcoholic steatohepatitis is an important risk factor for hepatobiliary cancer. These joint meetings will foster new and productive research collaborations towards both basic and translational advances, as well as offer valuable training opportunities for basic researchers and clinician scientists.
Scholarships for free registration poster abstract presentation opportunities available
March 22-24, 2021
ePoster / SciTalk Submission: March 11, 2021
Financial Aid Application: March 8, 2021
Attend our liver sessions at #ASIP2021 at #ExpBio!
- Symposium: The Gut Microbiota and Disease – Session I
- Minisymposium: Pathobiology of Liver Disease
- Symposium: The Gut Microbiota and Disease – Session II
- Symposium: Fixing Fatty Liver
- Club Hepatomania™ – Meet the Liver Experts – All Duct Up
- Symposium: Mechanisms of Hepatic Turmorgenesis